This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (25)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Clinical and Laboratory Studies

DEAN G. HUDSON, M.D.; GEORGE M. YOSHIHARA, M.S.; WILLIAM M. M. KIRBY, M.D.

AMA Arch Intern Med. 1956;97(1):57-61.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Spiramycin is a new antibiotic produced by a strain of Streptomyces isolated from soil samples in France.¹ The product was isolated by the French firm, Rohne-Poulenc Company. Sharp & Dohme, Division of Merck & Co., Inc., is exploring its clinical utility in the United States and supplied the spiramycin used in this study. The product is primarily a mixture of three chemical compounds, which can be separated but have not yet been completely differentiated. It is supplied in 0.5 gm. tablets, is hygroscopic, and has a bitter taste. Decomposition occurs rapidly at a pH lower than 4 or higher than 8. This report concerns laboratory studies and a clinical trial with spiramycin in 29 adult patients with bacterial pneumonia.

METHODS

Sensitivity Tests.

—Tests to determine the concentrations of spiramycin necessary to inhibit the growth of streptococci and pneumococci were carried out in tryptose phosphate broth containing 3% human blood. . . . [Full Text PDF of this Article]

Author Affiliations
Seattle

From the Department of Medicine, University of Washington School of Medicine, and the King County Hospital.

Footnotes
Submitted for publication Aug. 16, 1955.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?